Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24774488 | 0.94 | TAAR1 (0.38) | TMEM97SIGMAR1CHRNB2CHRNA4OPRL1 | |
| SCHEMBL24774474 | 0.84 | SIGMAR1 (0.37) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL24775499 | 0.83 | OPRM1 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL24774477 | 0.83 | OPRM1 (0.42) | CHRNB2CHRNA4OPRL1 | |
| SCHEMBL24775976 | 0.80 | CHRNA7 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL24775973 | 0.80 | CHRNA7 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL24775160 | 0.80 | CHRNA7 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL24775503 | 0.79 | GPR119 (0.41) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL24775427 | 0.78 | RIPK1 (0.33) | — | |
| SCHEMBL24775482 | 0.77 | RIPK1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | TMEM97 3314/4885SIGMAR1 4800/4885CHRNB2 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.